liraglutide - Medxy AI

Liraglutide Plus Metformin in Overweight/Obese PCOS: Greater Metabolic and Hormonal Benefits Than Metformin Alone

By MedXY 11/17/2025

A 2025 meta-analysis of 19 RCTs (n=1657) found liraglutide combined with metformin improved glycaemia, insulin resistance, BMI, sex hormones and lipids versus metformin alone in overweight or obese women with PCOS; evidence certainty was low due to heterogeneity and risk of bias.

Diabetes & Endocrinology news

Liraglutide Plus Metformin in Overweight/Obese PCOS: Greater Metabolic and Hormonal Benefits Than Metformin Alone

By MedXY 11/17/2025

Diabetes & Endocrinology Internal Medicine news

Comparative Efficacy and Safety of Tirzepatide, Semaglutide, and Liraglutide for Obesity Management: A Critical Review of Recent Cochrane Evidence

By MedXY 10/31/2025

This article critically compares the efficacy, safety, and long-term outcomes of tirzepatide, semaglutide, and liraglutide for the treatment of obesity based on recent Cochrane systematic reviews, highlighting differences in weight loss, adverse events, cardiovascular outcomes, and evidence certainty.

Clinical Updates news Ophthalmology Otorhinolaryngology Specialties

GLP-1 Receptor Agonists Linked to Early Risk of Optic Nerve Damage: A Case-Control Study Analysis

By MedXY 07/30/2025

GLP-1 receptor agonist use, especially liraglutide, is associated with a higher risk of nonarteritic anterior ischemic optic neuropathy (NAION) during the first year, particularly in patients without diabetes or obesity.